Cannabis
Lovelace Biomedical Report Evaluates Medical Cannabis and Traumatic Brain Injury (TBI)
Scientists at Lovelace Biomedical, led by their Mind Research Network subsidiary, and the University of New Mexico, have published a report in the latest issue of the Journal of Neurotrauma reviewing the evidence for medical cannabis in the treatment of traumatic brain injury (TBI).
The review identified significant gaps in the current understanding of the ability of medical cannabis to treat the many negative effects of TBI. Animal models of TBI suggest cannabinoids have neuroprotective and psychotherapeutic properties whereas human studies with recreational cannabis have consistently shown detrimental effects. The review identified a paucity of high-quality studies examining the beneficial and adverse effects of medical cannabis on traumatic brain injury, with only a single clinical study performed.
The authors note that observational studies demonstrate that TBI patients are using medical and recreational cannabis to treat their symptoms, highlighting inconsistencies between public policy, perception of potential efficacy, and the dearth of empirical evidence.
The full report, “Use of Medical Cannabis to Treat Traumatic Brain Injury,” is found here: https://doi.org/10.1089/neu.2020.7148
Cannabis
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
Cannabis
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
Cannabis
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
-
Cannabis2 weeks ago
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
Innocan1 week ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Curaleaf1 week ago
Curaleaf Completes Acquisition of Northern Green Canada
-
Cannabis1 week ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
SCHWAZZE3 days ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
-
Cannabis2 days ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
Humboldt2 days ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace